Evidence map›Paper›PMID 33524137›Full record

ArticleInternational journal of epidemiology2021

Reply to: Versatility of the clone-censor-weight approach: response to ''trial emulation in the presence of immortal-time bias''.

Camille Maringe, Sara Benitez Majano, Aimilia Exarchakou, Matthew Smith, Bernard Rachet, Aurélien Belot, Clémence Leyrat

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Camille MaringeInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0002-8739-9565
Sara Benitez MajanoInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0001-8032-9794
Aimilia ExarchakouInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Matthew SmithInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Bernard RachetInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Aurélien BelotInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Clémence LeyratInequalities in Cancer Outcomes Network, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0002-4097-4577

Funding

Cancer Research UK 18525Cancer Research UK 29018Cancer Research UK C7923/A18525Medical Research Council MR/M013278/1Medical Research Council MR/S01442X/1Medical Research Council MR/T032448/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiasClone CellsHumansTime Factors

Identifiers

PMID33524137
PMCPMC8128474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.